NovoCure Limited Ordinary Shares (NVCR) Stock Price

NVCRStock

$14.07+0.29%52W

Market Cap$1.64B

P/E—

PEG Ratio—

Div yield—

Beta1.12

NVCR Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)14.61%

Price vs S&P 500 (4W)-13.56%

VGM Score46.86

Book Value / Share (Quarterly)$2.90

P/TBV (Annual)3.02x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)6.81%

Cash Flow / Share (Quarterly)$-0.22

Price vs S&P 500 (YTD)-3.11%

Gross Margin (TTM)76.13%

Net Profit Margin (TTM)-21.25%

EPS (TTM)$-1.31

10-Day Avg Trading Volume1.69M

EPS Excl Extra (TTM)$-1.31

Revenue Growth (5Y)5.80%

EPS (Annual)$-1.22

ROI (Annual)-25.44%

Gross Margin (Annual)74.54%

Net Profit Margin (5Y Avg)-23.48%

Cash / Share (Quarterly)$3.78

Revenue Growth QoQ (YoY)15.60%

ROA (Last FY)-16.94%

Revenue Growth TTM (YoY)10.95%

EBITD / Share (TTM)$-1.22

ROE (5Y Avg)-35.83%

Operating Margin (TTM)-22.08%

Cash Flow / Share (Annual)$-0.67

P/B Ratio4.85x

P/B Ratio (Quarterly)5.19x

Net Income / Employee (Annual)$-84,900

EV / Revenue (TTM)2.49x

Net Interest Coverage (TTM)-15.06x

ROA (TTM)-15.85%

EV / EBITDA (TTM)1513.55x

EPS Incl Extra (Annual)$-1.22

Current Ratio (Annual)2.90x

Quick Ratio (Quarterly)2.70x

3-Month Avg Trading Volume1.51M

52-Week Price Return0.29%

Revenue / Employee (TTM)$435,600

Tangible BV / Share (Quarterly)$3.69

P/S Ratio (Annual)2.50x

Asset Turnover (Annual)0.81x

52-Week High$21.45

Operating Margin (5Y Avg)-24.46%

EPS Excl Extra (Annual)$-1.22

CapEx CAGR (5Y)12.22%

Tangible BV CAGR (5Y)31.18%

26-Week Price Return24.51%

Quick Ratio (Annual)2.57x

13-Week Price Return-11.62%

Total Debt / Equity (Annual)0.57x

Current Ratio (Quarterly)2.89x

Enterprise Value$1.74B

Revenue / Share Growth (5Y)5.31%

Asset Turnover (TTM)0.75x

Book Value / Share Growth (5Y)-8.26%

Revenue / Employee (Annual)$408,300

Inventory Turnover (Annual)4.38x

Pretax Margin (Annual)-20.79%

Cash / Share (Annual)$3.98

3-Month Return Std Dev77.29%

Gross Margin (5Y Avg)76.78%

Net Income / Employee (TTM)$-92,600

ROE (Last FY)-40.01%

Net Interest Coverage (Annual)-20.92x

EPS Basic Excl Extra (Annual)$-1.22

P/FCF (TTM)101.54x

Receivables Turnover (TTM)7.59x

Total Debt / Equity (Quarterly)0.58x

EPS Incl Extra (TTM)$-1.31

Receivables Turnover (Annual)8.01x

ROI (TTM)-22.07%

P/S Ratio (TTM)2.34x

Pretax Margin (5Y Avg)-21.01%

Revenue / Share (Annual)$5.88

Tangible BV / Share (Annual)$4.20

Price vs S&P 500 (52W)-15.25%

Year-to-Date Return8.82%

5-Day Price Return-4.42%

EPS Normalized (Annual)$-1.22

ROA (5Y Avg)-12.30%

Net Profit Margin (Annual)-20.79%

Month-to-Date Return-11.79%

Cash Flow / Share (TTM)$-1.76

EBITD / Share (Annual)$-1.25

Operating Margin (Annual)-23.47%

LT Debt / Equity (Annual)0.57x

ROI (5Y Avg)-15.89%

LT Debt / Equity (Quarterly)0.58x

EPS Basic Excl Extra (TTM)$-1.31

P/TBV (Quarterly)3.38x

P/B Ratio (Annual)4.25x

Inventory Turnover (TTM)4.00x

Pretax Margin (TTM)-21.84%

Book Value / Share (Annual)$3.03

Price vs S&P 500 (13W)-14.31%

Beta1.12x

P/FCF (Annual)173.74x

Revenue / Share (TTM)$6.03

ROE (TTM)-44.00%

52-Week Low$9.82

vGradeD

gGradeC

mGradeC

vgmGradeC

NVCR Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Jul 23, 2026	-$0.33	-$0.13	+60.80%(+$0.20)
Q1 2026	Apr 30, 2026	-$0.51	-$0.62	-20.89%(-$0.11)
Q4 2025	Feb 26, 2026	-$0.41	-$0.22	+46.53%(+$0.19)
Q3 2025	Oct 30, 2025	-$0.42	-$0.33	+21.39%(+$0.09)
Q2 2025	Jul 24, 2025	-$0.39	-$0.36	+7.35%(+$0.03)

NVCR Analyst Recommendations

Jun 2026

Jul 2026

Aug 2026

Sep 2026

4.08

3.92

Industry Peers — Surgical & Medical Instruments(142)

Symbol	Value Score	Growth Score	Momentum Score	P/S Ratio (TTM)	Revenue Growth (5Y)	Gross Margin (TTM)	Operating Margin (TTM)	Price
NVCRNovoCure Limited Ordinary Shares	D	C	C	2.3x	5.8%	76.1%	-22.1%	$14.07
SYKStryker Corporation	C	B	C	4.4x	11.8%	65.3%	21.3%	$294.66
MMM3M Company	C	D	B	3.4x	-5.0%	39.4%	18.4%	$164.75
BSXBoston Scientific Corp.	C	B	C	3.1x	15.2%	69.5%	19.8%	$44.39
BDXBecton, Dickinson and Co.	B	D	A	2.5x	6.3%	46.7%	9.6%	$191.75
MDLNMedline Inc. Class A common stock	C	D	C	1.6x	—	26.2%	6.0%	$35.96
RMDResMed Inc.	C	C	B	5.9x	12.1%	61.1%	33.4%	$238.97
DXCMDexCom, Inc.	C	B	B	6.5x	19.3%	64.3%	22.9%	$86.04
WSTWest Pharmaceutical Services, Inc.	D	C	A	8.5x	7.4%	36.8%	20.4%	$384.02
SOLVSolventum Corporation	C	C	B	1.8x	—	54.8%	23.9%	$85.81
BAXBaxter International Inc.	B	D	B	1.1x	-0.8%	30.7%	-2.3%	$25.28
PENPenumbra, Inc.	F	C	B	8.4x	20.2%	67.8%	12.4%	$320.86
GMEDGLOBUS MEDICAL INC	B	B	B	3.3x	30.1%	68.5%	20.6%	$76.71
PODDInsulet Corporation	C	A	C	3.2x	24.5%	71.1%	16.9%	$141.10
GKOSGlaukos Corporation	F	A	B	15.9x	17.7%	79.1%	-31.6%	$164.84
TFXTeleflex Incorporated	B	F	B	2.1x	-4.7%	53.8%	-11.7%	$130.43
HAEHaemonetics Corporation	C	C	A	4.0x	8.9%	59.1%	11.9%	$118.28
MMSIMerit Medical Systems Inc	C	B	B	3.4x	9.5%	49.5%	12.8%	$89.20
STVNStevanato Group S.p.A.	D	C	C	3.7x	12.4%	29.9%	16.4%	$18.90
MMEDMiniMed Group, Inc. Common Stock	—	—	B	—	—	—	—	$17.49
HTFLHeartflow, Inc. Common Stock	F	A	A	19.8x	—	80.1%	-40.8%	$48.29
ICUIICU Medical Inc	C	D	B	1.9x	11.9%	39.1%	3.5%	$162.99
IRTCiRhythm Holdings, Inc. Common Stock	D	B	C	4.3x	23.0%	71.5%	-3.0%	$108.66
PLSEPulse Biosciences, Inc Common Stock (DE)	F	—	A	2725.9x	—	0.3%	-7007.8%	$44.43
ATRCAtriCure, Inc.	D	B	A	5.0x	20.9%	76.3%	2.3%	$56.07
UFPTUFP Technologies Inc	C	B	A	3.6x	27.4%	28.5%	15.3%	$291.67
INSPInspire Medical Systems, Inc.	B	B	B	2.2x	51.2%	86.1%	6.0%	$68.79
LMATLeMaitre Vascular, Inc.	C	B	C	7.0x	14.0%	72.9%	29.5%	$80.82
KMTSKestra Medical Technologies, Ltd. Common Stock	F	A	B	15.2x	—	53.9%	-140.4%	$27.24
ATECAlphatec Holdings, Inc.	D	B	C	2.0x	39.5%	70.8%	-7.5%	$10.46
DRTSAlpha Tau Medical Ltd. Ordinary Shares	—	—	B	—	—	—	—	$12.29
TNDMTandem Diabetes Care, Inc.	D	C	C	1.1x	15.3%	56.0%	-4.4%	$16.24
IRMDiRadimed Corporation	D	B	B	13.1x	21.4%	75.9%	31.9%	$88.27
AORTArtivion, Inc.	C	C	C	2.3x	11.8%	64.4%	2.9%	$21.78
IARTIntegra LifeSciences Holdings	B	F	C	0.6x	3.6%	57.2%	4.0%	$13.21
PRCTPROCEPT BioRobotics Corporation Common Stock	C	A	D	3.0x	109.0%	64.2%	-33.9%	$17.57
BVSBioventus Inc. Class A Common Stock	B	C	A	1.9x	12.1%	68.7%	10.0%	$13.30
BBNXBeta Bionics, Inc. Common Stock	D	A	C	7.4x	—	58.3%	-69.8%	$16.35
SIBNSI-BONE, Inc. Common Stock	D	B	B	4.1x	22.3%	79.5%	-8.3%	$19.68
SGPSpyGlass Pharma, Inc. Common Stock	—	—	B	—	—	—	—	$24.00
MDXGMiMedx Group, Inc	C	D	C	1.8x	11.0%	78.8%	2.5%	$4.43
KIDSOrthoPediatrics Corp. Common Stock	C	B	B	2.3x	27.2%	73.7%	-11.9%	$21.95
TCMDTactile Systems Technology, Inc.	B	B	B	1.5x	12.0%	51.9%	10.0%	$22.52
SSIISS Innovations International Inc. Common Stock	F	A	D	9.7x	—	47.6%	-16.2%	$2.53
DCTHDelcath Systems Inc	D	C	B	5.1x	120.1%	87.0%	-1.9%	$14.08
ANGOAngioDynamics, Inc.	C	D	C	1.5x	1.9%	55.6%	-11.2%	$11.24
BWAYBrainsway Ltd. American Depositary Shares	D	B	B	9.5x	12.2%	74.9%	5.8%	$11.44
SGHTSight Sciences, Inc. Common Stock	D	B	A	5.5x	22.9%	88.4%	-33.4%	$8.28
CERSCerus Corp	D	C	C	1.8x	15.4%	57.2%	-0.7%	$2.18
NPCENeuropace, Inc. Common Stock	D	C	C	4.3x	19.4%	79.6%	-15.3%	$12.24
RCELAvita Medical, Inc. Common Stock	D	C	A	5.3x	19.6%	82.1%	-46.6%	$13.04

About NovoCure Limited Ordinary Shares

NovoCure Ltd is an oncology company that develops and commercializes Tumor Treating Fields (TTFields) devices, a proprietary technology platform for treating solid tumors. The company's approved products, Optune Gio and Optune Lua, treat glioblastoma, non-small cell lung cancer, and pancreatic cancer, while its pipeline includes Trident, Lunar-2, Panova-3, and Metis candidates. With headquarters in the United States, NovoCure generates the majority of its revenue domestically, with additional sales from Germany, Japan, and other international markets.